DR. STEVEN A. ROSENBERG, M.D.
Hospitals at Iron Gate Rd, Rockville, MD
License number
Maryland D0016562
Category
Hospitals
Type
Rehabilitation Unit
Address
Address
10104 Iron Gate Rd, Rockville, MD 20854
Phone
(301) 299-7670
Personal information
See more information about STEVEN A. ROSENBERG at radaris.comName
Address
Phone
5252 Ilex Way, Dayton, MD 21036
8752 Teresa Ln, Laurel, MD 20723
1 Chase St, Baltimore, MD 21202
8004 Maple Ave, Takoma Park, MD 20912
9356 Cherry Hill Rd, College Park, MD 20740
Organization information
See more information about STEVEN A. ROSENBERG at bizstanding.comSteven A Rosenberg MD
10104 Iron Gate Rd, Potomac, MD 20854
Categories:
Oncology Physicians & Surgeons, Physicians & Surgeons
Phone:
(301) 299-7670 (Phone)
Steven A Rosenberg
10104 Iron Gate Rd, Rockville, MD 20854
Status:
Inactive
Industry:
Medical Doctor's Office
Principal:
Steven Rosenberg (Principal)
Professional information
See more information about STEVEN A. ROSENBERG at trustoria.com
Melanoma Antigens And Their Use In Diagnostic And Therapeutic Methods
Melanoma Antigens And Their Use In Diagnostic And Therapeutic Methods
US Patent:
6537560, Mar 25, 2003
Filed:
May 5, 1998
Appl. No.:
09/073138
Inventors:
Yutaka Kawakami - Rockville MD
Steven A. Rosenberg - Potomac MD
Steven A. Rosenberg - Potomac MD
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 3900
US Classification:
4242771, 4241841, 4241851, 574 12, 574 13, 574 14, 574 15, 574 16, 574 17, 574 18
Abstract:
The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
Melanoma Antigens And Their Use In Diagnostic And Therapeutic Methods
Melanoma Antigens And Their Use In Diagnostic And Therapeutic Methods
US Patent:
5994523, Nov 30, 1999
Filed:
Jan 16, 1998
Appl. No.:
9/007961
Inventors:
Yutaka Kawakami - Rockville MD
Steven A. Rosenberg - Potomac MD
Steven A. Rosenberg - Potomac MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3900, C07H 2104, C12N 1563
US Classification:
536 235
Abstract:
The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
Modified T Cell Receptors And Related Materials And Methods
Modified T Cell Receptors And Related Materials And Methods
US Patent:
2012007, Mar 22, 2012
Filed:
Nov 28, 2011
Appl. No.:
13/304841
Inventors:
Paul F. Robbins - Potomac MD, US
Richard A. Morgan - Columbia MD, US
Steven A. Rosenberg - Potomac MD, US
Alan David Bennett - Oxfordshire, GB
Richard A. Morgan - Columbia MD, US
Steven A. Rosenberg - Potomac MD, US
Alan David Bennett - Oxfordshire, GB
Assignee:
Immunocore Limited - Oxfordshire
The United States of America, as represented by the Secretary, Dept. of Health & Human Services - Bethesda MD
The United States of America, as represented by the Secretary, Dept. of Health & Human Services - Bethesda MD
International Classification:
A61K 38/02, A61P 31/00, C12Q 1/02, A61P 35/00
US Classification:
514 193, 514 11, 435 29
Abstract:
The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8 T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
T Cell Receptors And Related Materials And Methods Of Use
T Cell Receptors And Related Materials And Methods Of Use
US Patent:
2012001, Jan 19, 2012
Filed:
Jan 25, 2010
Appl. No.:
13/146531
Inventors:
Steven A. Rosenberg - Potomac MD, US
Richard A. Morgan - Columbia MD, US
Timothy L. Frankel - New York NY, US
Peter Peng - Baltimore MD, US
Richard A. Morgan - Columbia MD, US
Timothy L. Frankel - New York NY, US
Peter Peng - Baltimore MD, US
International Classification:
A61K 38/17, C07H 21/04, C12N 15/63, A61P 35/00, C12N 5/10, C12N 1/13, C12N 1/15, C12N 1/21, C07K 14/725, G01N 33/574
US Classification:
514 193, 530350, 536 235, 4353201, 435 723, 435419, 435325, 4352572, 43525411, 435366, 43525233, 435361, 435364, 435365, 435369, 4353723, 514 212
Abstract:
The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.
Activated Dual Specificity Lymphocytes And Their Methods Of Use
Activated Dual Specificity Lymphocytes And Their Methods Of Use
US Patent:
7723111, May 25, 2010
Filed:
Mar 9, 2001
Appl. No.:
09/803578
Inventors:
Patrick Hwu - Potomac MD, US
Michael H. Kershaw - Rockville MD, US
Steven A. Rosenberg - Potomac MD, US
Michael H. Kershaw - Rockville MD, US
Steven A. Rosenberg - Potomac MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 15/00, C12N 5/08, A61K 48/00
US Classification:
435455, 424 931, 424 932, 424 9321, 435372, 4353723, 435375
Abstract:
The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.
Methods And Compositions For Transforming Dendritic Cells And Activating T Cells
Methods And Compositions For Transforming Dendritic Cells And Activating T Cells
US Patent:
7378277, May 27, 2008
Filed:
Jun 26, 2003
Appl. No.:
10/607327
Inventors:
Patrick Hwu - Rockville MD, US
Mark Reeves - Grand Terrace CA, US
Steven A. Rosenberg - Potomac MD, US
Mark Reeves - Grand Terrace CA, US
Steven A. Rosenberg - Potomac MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 15/00, C12N 15/74, C12N 5/00, C12N 5/08
US Classification:
435455, 4353201, 435325, 435372, 435377, 424 9321, 424 9371
Abstract:
Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.
Antibodies To The Protein Product Encoded By Orf3 Of The Trp-1 Gene And Compositions And Kits Thereof
Antibodies To The Protein Product Encoded By Orf3 Of The Trp-1 Gene And Compositions And Kits Thereof
US Patent:
7015312, Mar 21, 2006
Filed:
May 16, 2000
Appl. No.:
09/571313
Inventors:
Rong-Fu Wang - Bethesda MD, US
Steven A. Rosenberg - Potomac MD, US
Steven A. Rosenberg - Potomac MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C07K 16/00
US Classification:
53038885, 5303871, 4241301, 4241561
Abstract:
The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The products of this gene are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.
Heterologous Boosting Immunizations
Heterologous Boosting Immunizations
US Patent:
2005010, May 12, 2005
Filed:
Dec 8, 2004
Appl. No.:
11/007115
Inventors:
Ronald Chamberlain - North Potomac MD, US
Kari Irvine - Washington DC, US
Steven Rosenberg - Potomac MD, US
Nicholas Restifo - Washington DC, US
Kari Irvine - Washington DC, US
Steven Rosenberg - Potomac MD, US
Nicholas Restifo - Washington DC, US
Assignee:
The Government of the United States of America, as Represented by the Secretary, Department of Healt - Rockville MD
International Classification:
A61K039/275, A61K039/285, A61K048/00
US Classification:
424232100, 514044000
Abstract:
This invention describes methods of vaccination for the effective generation of an antigen-specific immune response. More particularly, this invention describes the use of heterologous vaccination vectors for eliciting an enhanced boosting immunization response. Methods of treatment and prevention of diseases using the vaccination schemes of the invention are also provided.
Chimeric Receptor Genes And Cells Transformed Therewith
Chimeric Receptor Genes And Cells Transformed Therewith
US Patent:
8211422, Jul 3, 2012
Filed:
Oct 24, 1995
Appl. No.:
08/547263
Inventors:
Zelig Eshhar - Rehovot, IL
Daniel Schindler - Rehovot, IL
Tova Waks - Petach Tikva, IL
Gideon Gross - Hevel KoraZim, IL
Steven A. Rosenberg - Potomac MD, US
Patrick Hwu - Rockville MD, US
Daniel Schindler - Rehovot, IL
Tova Waks - Petach Tikva, IL
Gideon Gross - Hevel KoraZim, IL
Steven A. Rosenberg - Potomac MD, US
Patrick Hwu - Rockville MD, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
Yeda Research and Development Co., Ltd. - Rehovot
Yeda Research and Development Co., Ltd. - Rehovot
International Classification:
A61K 48/00
US Classification:
424 9321, 424 9371, 514 44 R
Abstract:
Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
Activated Dual Specificity Lymphocytes And Their Methods Of Use
Activated Dual Specificity Lymphocytes And Their Methods Of Use
US Patent:
2010015, Jun 24, 2010
Filed:
Mar 2, 2010
Appl. No.:
12/715829
Inventors:
Patrick Hwu - Houston TX, US
Michael H. Kershaw - Victoria, AU
Steven A. Rosenberg - Potomac MD, US
Michael H. Kershaw - Victoria, AU
Steven A. Rosenberg - Potomac MD, US
Assignee:
The U.S.A. as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
International Classification:
A61K 35/26, C12N 5/00, C12N 5/071
US Classification:
424 9321, 435325, 4353723
Abstract:
The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.